Literature DB >> 7768489

Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm.

J Debord1, C Pessis, J C Voultoury, P Marquet, H Lotfi, L Merle, G Lachâtre.   

Abstract

The population pharmacokinetics of amikacin was studied in 40 intensive care unit patients (212 plasma concentrations) by NPEM algorithm using a one-compartment model. The population was best characterized by the following pharmacokinetic parameters: renal clearance relative to creatinine clearance (Cs = 0.96 +/- 0.33), and either the total volume of distribution (Vd = 23.9 +/- 7.0 l) or the volume of distribution relative to body weight (Vs = 0.36 +/- 0.10 l.kg-1. The volume of distribution was increased with respect to the usual value of 0.25 l.kg-1. The statistical distribution of these pharmacokinetic parameters was approximately gaussian, with no significant correlation between volume of distribution and clearance. The medians and standard deviations of Cs and Vs were used as reference population values to estimate the pharmacokinetics of amikacin in a second group of 29 patients by the bayesian method, with two blood samples per patient. For each patient, the fitted parameters were able to predict the plasma concentrations of amikacin during the next 72 h with no significant bias and good precision (2.9 mg.l-1 for peaks and 0.5 mg.l-1 for troughs). This study confirms the ability of the NPEM algorithm to provide reference population values for use in bayesian monitoring of aminoglycoside therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768489     DOI: 10.1111/j.1472-8206.1995.tb00266.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  12 in total

1.  Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.

Authors:  Sílvia M Illamola; Hoa Q Huynh; Xiaoxi Liu; Zubin N Bhakta; Catherine M Sherwin; Theodore G Liou; Holly Carveth; David C Young
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 2.  Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.

Authors:  Amélie Marsot; Romain Guilhaumou; Camille Riff; Olivier Blin
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

3.  Renal elimination of amikacin and the aging process.

Authors:  M Ducher; P Maire; C Cerutti; Y Bourhis; F Foltz; P Sorensen; R Jelliffe; J P Fauvel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 5.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

6.  Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina.

Authors:  Muhammad Jamshaid; Samia Yousuf; Nadeem Irfan Bukhari; Amir Ali Rizvi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

7.  Bayesian pharmacokinetics of gentamicin in a haemodialysis population.

Authors:  Lavern M Vercaigne; Robert E Ariano; James M Zacharias
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients.

Authors:  S Romano; M Del Mar Fdez de Gatta; V Calvo; E Mendez; A Domínguez-Gil; J M Lanao
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.

Authors:  Cédric Carrié; Faustine Delzor; Stéphanie Roure; Vincent Dubuisson; Laurent Petit; Mathieu Molimard; Dominique Breilh; Matthieu Biais
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

10.  Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.

Authors:  Norma A Aréchiga-Alvarado; Susanna E Medellín-Garibay; Rosa Del C Milán-Segovia; Arturo Ortiz-Álvarez; Martín Magaña-Aquino; Silvia Romano-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.